iCareDx Announces Appointment Of Advisory Board

NEW YORK–(BUSINESS WIRE)– iCareDx, Inc., a biotechnology company focused on blood-based early
detection of cancer, today announced the formation of an Advisory Board,
comprised of renowned scientists, clinicians and business leaders in the
areas of oncology and diagnostics. The Advisory Board’s role will be to
provide valuable scientific, clinical and business insights, along with
strategic guidance in decision-making, as the Company seeks to advance
its blood-based screening tests for early detection of colorectal cancer
as well as for early detection in pan-oncology.

“We are honored to welcome such outstanding authorities in their
respective areas to our advisory board to support the development of
iCareDx’s early detection screening technologies,” said Dr. Bernard
Peperstraete, the Chief Executive Officer of iCareDx. “In forming the
company’s inaugural Advisory Board, we are seeking to further position
iCareDx to successfully pursue a highly accurate and cost-effective
approach for early cancer detection, and to ultimately help reduce
cancer deaths.”

Over the past years, the design of iCareDx’s molecular detection
technologies was led by Francis Barany, PhD, Professor of Microbiology
and Immunology at the Weill Cornell Medicine. Dr. Barany is a prolific
inventor with 52 issued US patents, which are foundational inventions in
molecular diagnostics and next generation sequencing, and include the
ligase chain reaction (LCR), the ligase detection reaction (LDR), and
the Universal DNA array. “We have assembled this team of thought
leaders to guide our efforts in advancing our platform for blood-based
early cancer detection,” said Dr. Francis Barany. “Our scalable,
low-cost cancer detection platforms are designed to vastly improve
cancer care, ultimately throughout the world.”

Composition of iCareDx’s Advisory Board:

• Mr. Haywood Cochrane. Previously, CEO at CHD Meridian Corp (now
  part of Walgreens), at Allied Clinical Labs and at Take Care Employer
  Solutions; EVP, CFO and Treasurer at LabCorp, COO at Biomedical
  Reference Labs, SVP North-America Diagnostics and COO at Roche
  Biomedical labs; Director at Tripath Imaging, American Esoteric Labs,
  Sonus Corp., Ameripath, Unilab Corp.
• Dr. Paolo Fortina. Professor of Cancer Biology and
  Medical Oncology at the Sidney Kimmel Medical College, Director of the
  NCI-designated Cancer Genomics Laboratory at the Sidney Kimmel Cancer
  Center, Thomas Jefferson University.
• Dr. David Gelfand. Previously, Vice President, Discovery
  Research Division and Director for the Program in Core Research at
  Roche Molecular Systems, CSO of WaferGen BioSystems, and a consultant
  at the Centre National de Génotypage in France, inventor of the
  real-time PCR (“TaqMan”) technology and many thermostable DNA
  Polymerases and Reverse Transcriptases.
• Dr. Larry J. Kricka. Professor of Pathology & Laboratory
  Medicine at the University of Pennsylvania Director of the General
  Chemistry and Endocrinology Laboratory at the Hospital of the
  University of Pennsylvania.
• Dr. Christopher Mason. Associate Professor Computational
  Genomics at Weill Cornell Medicine, with appointments at Department of
  Physiology and Biophysics, Institute for Computational Biomedicine,
  Meyer Cancer Center, Feil Family Brain and Mind Research Institute.
  WorldQuant Foundation Research Scholar. Affiliate Fellow of Genomics,
  Ethics, and Law, ISP, Yale Law School.
• Dr. Kenneth Offit. Chief of Clinical Genetics Service at
  Memorial Sloan-Kettering Cancer Center, Member of the Program in
  Cancer Biology and Genetics at the Sloan-Kettering Institute,
  Professor of Medicine and Public Health at the Weill Cornell Medicine.
• Dr. Mark Pochapin. Sholtz/Leeds Professor, Director of
  Gastroenterology, Professor of Medicine at NYU Langone Medical Center.
  Advanced gastrointestinal endoscopy, and the prevention, early
  detection, and treatment of gastrointestinal cancers.

About iCareDx Inc.

iCareDx is a biotechnology company focused on developing technologies
for blood-based early detection of cancer. iCareDx’s technology allows
for highly accurate screening of blood to detect cancer markers at the
early cancer stages, before the cancer becomes untreatable. Backed by a
highly experienced team, it is iCareDx’s mission to contribute to the
global battle against cancer by detecting and attacking cancer through
high-precision, early detection.

For more information, please visit www.icaredx.com,
or contact us at info@icaredx.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160516006730/en/